Study of Teduglutide in Japanese Participants With Short Bowel Syndrome

A 24-Week Safety, Efficacy, Pharmacokinetic Study of Teduglutide in Japanese Subjects With Short Bowel Syndrome Who Are Dependent on Parenteral Support

The objectives of this clinical study are to evaluate the safety, efficacy, and pharmacokinetics (PK) of teduglutide in Japanese participants with short bowel syndrome (SBS) who are dependent on parenteral nutrition/intravenous (PN/IV) over a 24-week treatment period.

Study Overview

• Status: Completed
• Conditions: Short Bowel Syndrome
• Intervention / Treatment: Drug: Teduglutide; Device: Syringe; Device: Needle; Device: Vial Adapter for Device

• Study Type: Interventional
• Enrollment (Actual): 7
• Phase: Phase 3

Contacts and Locations

Study Locations

• Japan
  • Hyogo, Japan, 663-8501
    • Hyogo College of Medicine Hospital
  • Miyagi-Ken, Japan, 980-8574
    • Tohoku University Hospital
  • Osaka, Japan, 565-0871
    • Osaka University Hospital
  • Yokohama, Japan, 240-8555
    • Yokohama Municipal Citizen's Hospital
  • Hiroshima-ken
    • Hiroshima-shi, Hiroshima-ken, Japan, 734-8551
      • Hiroshima University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Ability to voluntarily provide written, signed, and informed consent to participate in the study.
2. Male or female 16 years of age or older at the time of signing informed consent.
3. Intestinal failure due to short bowel syndrome (SBS) as a result of major intestinal resection (example, due to injury, volvulus, vascular disease, cancer, Crohn's disease) that resulted in at least 12 continuous months of parenteral nutrition/intravenous (PN/IV) dependence at the time of informed consent.
4. Parenteral nutrition requirement of at least 3 times per week during the week before the screening visit and during the 2 weeks prior to the baseline visit.
5. Stable PN/IV requirement for at least 4 consecutive weeks immediately prior to the start of teduglutide treatment. Stability is defined as: a. Actual PN/IV usage is similar to prescribed PN/IV; b. Baseline (Visit 2) 48-hour oral fluid intake and urine output (I/O) volumes fall within +/- 25 percent (%) of the respective 48-hour I/O volumes at the last optimization visit; c. Urine output volume should NOT fall below 2 liter (L) and should not exceed 4 L per 48 hours at the last optimization visit, the stabilization visit, and the baseline visit.
6. For participants with a history of Crohn's disease, clinical remission for at least 12 weeks prior to the baseline visit as demonstrated by clinical assessment, which may include procedure-based evidence of remission.
7. Females of childbearing potential must agree to comply with the contraceptive requirements of the protocol.
8. An understanding, ability, and willingness to fully comply with study procedures and restrictions.

Exclusion Criteria:

1. Participation in a clinical study using an experimental drug within 30 days or 5.5 halflives, whichever is longer, prior to screening, or concurrent participation in any other clinical study.
2. Use of glucagon-like peptide (GLP)-2 or human growth hormone or analogs of these hormones within the past 6 months.
3. Use of octreotide, GLP-1 analogs, dipeptidyl peptidase-IV inhibitors, or enteral glutamine within 30 days.
4. Previous use of teduglutide.
5. Participants with active inflammatory bowel disease (IBD) or participants with IBD who received a change in immunosuppressant therapy (example, azathioprine, anti- tumor necrosis factor (TNFs)) within the past 6 months.
6. Intestinal malabsorption due to a genetic condition, such as cystic fibrosis, microvillus inclusion disease, familial adenomatous polyposis, etc.
7. Chronic intestinal pseudo-obstruction or severe dysmotility.
8. Clinically significant intestinal stenosis or obstruction, or evidence of such on upper gastrointestinal (GI) series with small bowel follow-through, within the past 6 months.
9. Major GI surgical intervention, including bowel lengthening procedures, within the past 3 months (insertion of feeding tube or endoscopic procedure is allowed).
10. Unstable cardiac disease, (example, congestive heart failure, cyanotic disease, or congenital heart disease).
11. Moderate or severe renal impairment, defined as creatinine clearance less than (<) 50 millilitre (ml)/ minute (min).
12. Currently diagnosed with cancer or a history of any cancer except surgically curative skin cancer within the past 5 years.
13. Severe hepatobiliary disease including: a. Total bilirubin level greater than or equal to (>=) 2 times the upper limit of normal (ULN); b. Aspartate aminotransferase (AST) >=5 times ULN; c. Alanine aminotransferase (ALT) >=5 times ULN.
14. Active clinically significant pancreatic disease, including clinical signs of pancreatitis associated with elevations in serum amylase or lipase >=2 times ULN.
15. More than 4 SBS-related or PN/IV-related hospital admissions (example, central line associated bloodstream infection, bowel obstruction, severe fluid/electrolyte disturbances) within the past 12 months.
16. Unscheduled hospitalization within 30 days prior to screening.
17. Pregnant or lactating female.
18. Any condition or circumstance that in the investigator's opinion put the participant at any undue risk, prevent completion of the study, or interfere with analysis of the study results.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Teduglutide 0.05 mg; Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.

Drug: Teduglutide; Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.; Device: Syringe; Teduglutide will be administered using syringe. Syringe is approved for use in Japan by Pharmaceuticals and Medical Devices Agency (PMDA).; Device: Needle; Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.; Device: Vial Adapter for Device; Vial adapter for device is approved for use in Japan by PMDA.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)	Change from baseline in weekly PS volume at EOT/ET was reported.	Baseline, EOT/ET (up to Week 28)
Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)	Percent change from baseline in weekly PS volume at EOT/ET was reported.	Baseline, EOT/ET (up to Week 28)
Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 20	Percentage of participants who achieved at least 20% reduction from baseline in weekly PS volume at Week 20 was reported.	Baseline, Week 20
Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 24	Percentage of participants who achieved at least 20% reduction from baseline in weekly PS volume at Week 24 was reported.	Baseline, Week 24
Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)	Percentage of participants who achieve at least 20% reduction from baseline in weekly PS at EOT/ET was reported.	Baseline, EOT/ET (up to Week 28)
Change From Baseline in Days Per Week of Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET)	Change from baseline in days per week of PS at EOT/ET was reported.	Baseline, EOT/ET (up to Week 28)
Change From Baseline in Plasma Citrulline Levels at End of Treatment/Early Termination (EOT/ET)	Plasma citrulline levels were measured as a biomarker of enterocyte mass. Change from baseline in plasma citrulline levels up to EOT/ET was reported.	Baseline, EOT/ET (up to Week 28)
Number of Participants Who Were Completely Weaned Off Parenteral Support (PS) at Week 24/End of Treatment (EOT)	Number of participants who were completely weaned off PS at Week 24/EOT was reported.	Week 24/EOT
Area Under the Plasma Concentration-Time Curve From Zero to the Last Measurable Concentration (AUC0-t) of Teduglutide	AUC0-t of teduglutide was reported.	Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Maximum Plasma Concentration (Cmax) of Teduglutide	Cmax of teduglutide was reported.	Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Time to Maximum Plasma Concentration (Tmax) of Teduglutide	Tmax of teduglutide was reported.	Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Terminal-phase Half-life (T1/2) of Teduglutide	T1/2 of teduglutide was reported.	Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Apparent Clearance (CL/F) of Teduglutide	CL/F of teduglutide was reported.	Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Apparent Volume of Distribution (Vz/F) of Teduglutide	Vz/F of teduglutide was reported.	Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours Post-dose on Day 1; Pre-dose, 1, 2 hours Post-dose on Week 4 or Week 12
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)	An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs whose onset occurred, severity worsened, or intensity increased after receiving the study medication.	From start of study drug administration up to EOT/ET (up to Week 28)
Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG)	12-lead ECG was performed at the study center after the participant has been resting for at least 5 minutes. Number of participants with clinically significant abnormalities in 12-Lead ECG was reported.	From start of study drug administration up to EOT/ET (up to Week 28)
Change From Baseline in Blood Pressure at End of Treatment/Early Termination (EOT/ET)	Change from baseline in systolic and diastolic blood pressure at EOT/ET was reported.	Baseline, EOT/ET (up to Week 28)
Change From Baseline in Pulse Rate at End of Treatment/Early Termination (EOT/ET)	Change from baseline in pulse rate at EOT/ET was reported.	Baseline, EOT/ET (up to Week 28)
Change From Baseline in Body Temperature at End of Treatment/Early Termination (EOT/ET)	Change from baseline in body temperature at EOT/ET was reported.	Baseline, EOT/ET (up to Week 28)
Change From Baseline in Hemoglobin at End of Treatment/Early Termination (EOT/ET)	Change from baseline in hemoglobin at EOT/ET was reported.	Baseline, EOT/ET (up to Week 28)
Change From Baseline in Hematocrit at End of Treatment/Early Termination (EOT/ET)	Change from baseline in hematocrit at EOT/ET was reported.	Baseline, EOT/ET (up to Week 28)
Change From Baseline in Serum Blood Urea Nitrogen (BUN) at End of Treatment/Early Termination (EOT/ET)	Change from baseline in serum blood urea nitrogen at EOT/ET was reported.	Baseline, EOT/ET (up to Week 28)
Change From Baseline in Creatinine at End of Treatment/Early Termination (EOT/ET)	Change from baseline in creatinine at EOT/ET was reported.	Baseline, EOT/ET (up to Week 28)
Change From Baseline in Urine Sodium at End of Treatment/Early Termination (EOT/ET)	Change from baseline in urine sodium at EOT/ET was reported.	Baseline, EOT/ET (up to Week 28)
Number of Participants Who Reported Positive Specific Antibodies to Teduglutide at End of Treatment/Early Termination (EOT/ET)	Number of participants who reported positive specific antibodies to teduglutide at EOT/ET was reported.	EOT/ET (up to Week 28)
Change From Baseline in 48-Hour Urine Output at End of Treatment/Early Termination (EOT/ET)	Change from baseline in 48-hour urine output at EOT/ET was reported.	Baseline, EOT/ET (up to Week 28)
Change From Baseline in Body Weight at End of Treatment/Early Termination (EOT/ET)	Change from baseline in body weight at EOT/ET was reported.	Baseline, EOT/ET (up to Week 28)
Change From Baseline in Body Mass Index (BMI) at End of Treatment/Early Termination (EOT/ET)	Change from baseline in BMI at EOT/ET was reported.	Baseline, EOT/ET (up to Week 28)
Number of Participants With Abnormal Clinically Significant Changes in Gastrointestinal (GI) Specific Tests at Week 24/ET (Early Termination)	GI specific tests included colonoscopy or sigmoidoscopy, abdominal ultrasound, upper GI series with small bowel follow-through (UGI/SBFT). Number of participants with abnormal clinically significant changes in gastrointestinal specific tests at Week 24/ET was reported.	Week 24/ET

Collaborators and Investigators

• Sponsor: Shire

Study record dates

Study Major Dates

• Study Start (Actual): July 6, 2018
• Primary Completion (Actual): August 6, 2019
• Study Completion (Actual): August 6, 2019

Study Registration Dates

• First Submitted: August 28, 2018
• First Submitted That Met QC Criteria: September 6, 2018
• First Posted (Actual): September 10, 2018

Study Record Updates

• Last Update Posted (Actual): August 4, 2020
• Last Update Submitted That Met QC Criteria: July 17, 2020
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Postoperative Complications; Disease; Gastrointestinal Diseases; Intestinal Diseases; Malabsorption Syndromes; Syndrome; Short Bowel Syndrome; Physiological Effects of Drugs; Gastrointestinal Agents; Protective Agents; Radiation-Protective Agents; Teduglutide
• Other Study ID Numbers: SHP633-306

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, …).

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No